Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,462 | 401 | 3,006 |
| Samples | 859 | 170 | 678 |
| Peptides | 721 | 123 | 602 |
Function
BCOR · BCL6 corepressor
The protein encoded by this gene was identified as an interacting corepressor of BCL6, a POZ/zinc finger transcription repressor that is required for germinal center formation and may influence apoptosis. This protein selectively interacts with the POZ domain of BCL6, but not with eight other POZ proteins. Specific class I and II histone deacetylases (HDACs) have been shown to interact with this protein, which suggests a possible link between the two classes of HDACs. Several transcript variants encoding different isoforms have been found for this gene. A pseudogene of this gene is found on chromosome Y.[provided by RefSeq, Jun 2010].
Isoforms & Proteins
6 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 695 amino-acid changes on canonical ENST00000378444 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in BCOR · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in BCOR – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 8/40 20% | 0/0 0% |
| Endometrial Carcinoma | 6/42 14% | 74/612 12% |
| Glioblastoma | 5/98 5% | 0/0 0% |
| Melanoma | 15/210 7% | 88/1899 5% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Cervical Carcinoma | 4/35 11% | 12/422 3% |
| Non-Small Cell Lung Carcinoma | 19/304 6% | 39/1390 3% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 22/752 3% |
| Colorectal Carcinoma | 26/143 18% | 68/3239 2% |
| Neuroendocrine Tumour | 12/154 8% | 8/577 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 22/810 3% |
| Ovarian Carcinoma | 11/109 10% | 17/998 2% |
| Gastric Carcinoma | 4/74 5% | 43/1809 2% |
| Other Solid Cancers | 5/94 5% | 32/1515 2% |
| Other Sarcomas | 1/69 1% | 16/699 2% |
| Burkitts Lymphoma | 4/32 12% | 1/196 1% |
| Adrenocortical Carcinoma | 0/3 0% | 2/112 2% |
| Bladder Carcinoma | 1/58 2% | 16/956 2% |
| Breast Carcinoma | 11/144 8% | 46/3264 1% |
| Head and Neck Carcinoma | 7/85 8% | 19/1574 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Non-Cancerous | 1/104 1% | 9/830 1% |
| Glioma | 0/52 0% | 23/2127 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 17/1592 1% |
| B-Cell Non-Hodgkins Lymphoma | 5/88 6% | 22/2534 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Hepatocellular Carcinoma | 2/46 4% | 19/2210 1% |
| Ewings Sarcoma | 1/63 2% | 2/262 1% |
| Plasma Cell Myeloma | 2/44 5% | 1/305 0% |
Mutation Distribution
Where BCOR is mutated · all tissues, split by cell line vs tissue
How many mutations in BCOR were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,462 mutations in BCOR
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|